Natasha B. Hunter, MD

In those with DLBCL, Burkitt lymphoma, and Hodgkin lymphoma, cure is often achieved. Furthermore, in the salvage setting, whether auto-HCT or allo-HCT is used, the same appears to be true. A great deal of progress has been made in the treatment of lymphoma in patients with HIV infection, but more remains to be done before outcomes are comparable to those of the general population.

Advances in basic science and clinical medicine in the past few decades have increasingly elevated the profile of personalized medicine, ie, the identification of individual tumor or biologic features that offer targets for therapy.